Unit
- Core definition: Lewy Body Dementia (LBD) is a progressive neurodegenerative disorder marked by abnormal protein clumps called Lewy bodies in brain regions controlling cognition, movement, and behavior. It ranks as the second most common dementia after Alzheimer's disease but is often underdiagnosed.
- Two clinical subtypes: Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD) share the same pathology but differ by timing of symptom onset. DLB presents with cognitive decline before or within one year of parkinsonism; PDD occurs when dementia develops years after Parkinson's motor symptoms.
- Key pathological feature: Lewy bodies are composed primarily of alpha-synuclein protein. Their distribution in cortical and subcortical areas correlates with the pattern of cognitive, psychiatric, and motor impairments seen in LBD.
- Neurotransmitter deficits: LBD involves significant loss of acetylcholine and dopamine. Acetylcholine depletion contributes to cognitive fluctuations and visual hallucinations; dopamine loss leads to parkinsonism features like rigidity and bradykinesia.
- Overlap with other dementias: Many LBD patients also have Alzheimer's pathology (amyloid plaques and tau tangles). Mixed pathology can complicate diagnosis and influence disease progression and treatment response.
- Clinical heterogeneity: Presentation varies widely among individuals. Some experience prominent hallucinations early; others have severe motor impairment or sleep disorders. This variability challenges recognition and standardized management.
- Importance of accurate diagnosis: Misdiagnosis is common, with LBD often mistaken for Alzheimer's or vascular dementia. Correct identification is crucial because LBD patients have unique sensitivities to medications, especially antipsychotics, which can cause severe adverse reactions.
- Disease course: LBD progresses gradually but with fluctuations in cognition and alertness. Mean survival after diagnosis ranges from 5 to 8 years, though this varies based on age, comorbidities, and care quality.
- Diagnostic criteria: The consensus criteria for probable DLB require two or more core clinical features including fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and parkinsonism. Supportive features include severe neuroleptic sensitivity, falls, and autonomic dysfunction such as orthostatic hypotension.
- Nonpharmacologic interventions: Management emphasizes structured routines, environmental modifications to reduce sensory overload, and cognitive stimulation tailored to fluctuating attention. Physical therapy helps balance and gait, while occupational therapy addresses visual spatial deficits and safety at home. Caregiver education is essential to manage behavioral symptoms without medications.
- Medication management: Cholinesterase inhibitors like rivastigmine and donepezil are first line for cognitive and psychiatric symptoms. Levodopa may help motor symptoms but often provides limited benefit. Antipsychotics are generally avoided due to risk of severe extrapyramidal reactions and neuroleptic malignant syndrome; if necessary, quetiapine or clozapine are preferred with careful monitoring.
Scope of Practice
Role: Healthcare Administrator Supporting LBD Services
Within scope:
- Developing educational materials for staff on LBD recognition and care pathways
- Coordinating referrals to neurology, psychiatry, and geriatric specialists
- Ensuring policies align with dementia-friendly care standards and regulatory requirements
- Facilitating support groups and resources for caregivers
- Tracking quality metrics related to dementia diagnosis and management
Outside scope:
- Diagnosing LBD or interpreting clinical assessments
- Prescribing medications or adjusting treatment regimens
- Providing direct patient care beyond administrative coordination
- Making independent clinical decisions about patient management
Quick Revision
- LBD is a common but underdiagnosed dementia with Lewy bodies as the pathological hallmark.
- Two subtypes exist: DLB and PDD, distinguished by timing of cognitive versus motor symptoms.
- Neurotransmitter deficits affect cognition, movement, and behavior in unique ways.
- Accurate diagnosis is vital due to medication sensitivities and distinct management needs.